Denying patients a life-saving medicine for inexplicable reasons is the wrong kind of change. If Marty Makary doesn’t understand that, the FDA needs a change in leadership. on.wsj.com/4tD5K4c

🚨: First human trial for age reversal gene therapy gets FDA green light

The clock is ticking for the FDA on $QURE. With Phase I/II data showing a 75% slowing in Huntington’s disease progression, the pressure is mounting. As patient functional videos start to go viral, the ethical outcry against a long-term sham-controlled Phase III is becoming

$qure $clpt Sung on Amt 130 youtu.be/YlQMaozHEh0

I am so proud of our community as they continue to #StandUpSpeakUp4HD by speaking to their Congressmen about #huntingtonsdisease and what is going on with the U.S. FDA! Thank you for your advocacy, Casey!! #ActWithUrgency #TimeMatters #DelayStealsTime Rep. Jake Auchincloss 🟧 Senate Aging Committee

$SLS Smart money moving. Vanguard adds → BlackRock doubles position in latest 13G. This is the exact same institutional buying pattern we saw in $NKTR days before their big data move. History rhymes?

$NKTR Jefferies new blurb out like $NKTR's AA opportunity, which is still under- appreciated as the potential 1st biologic approval to expand to an ~$2B+ market.

$SLS Sellas Life Science - Stergiou's Sunday Message: 80-Event Announcement Imminent. Shorts, the exit is closing. 🚀 #ShortSqueeze #Biotech #REGAL

Strategic Add: $NKTR @ $83.39 📈 The institutions just paid $92.00 for 4 million shares. Grabbing more today at a nearly 10% discount to the "Big Money" buy-in. I treat everything like real estate: buy high-quality assets and wait. Regardless of the daily grind, I’m holding for

$QURE I'd love to do this walk/run with uniQure staff for Fabry Awareness.

$QURE uniQure is proving they don't need to wait for the US FDA to find a path to market. uniqure.gcs-web.com/node/12636/pdf

Now the markets can finally breathe, with this guy out the way. 👋 #realestateinvesting #Valueinvesting #Stockinvesting